Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdigones N, Chin SF, Farooq M, Mejia R, Cronin PA, Anderson KS, Kosiorek HE, Northfelt DW, McCullough AE, Patel BK, Weitzel JN, Slavin TP, Caldas C, Pockaj BA, Murtaza M.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaax7392. doi: 10.1126/scitranslmed.aax7392.

PMID:
31391323
2.

Predictive factors of upstaging DCIS to invasive carcinoma in BCT vs mastectomy.

Sheaffer WW, Gray RJ, Wasif N, Stucky CC, Cronin PA, Kosiorek HE, Basu A, Pizzitola VJ, Patel B, Giurescu ME, Lorans R, McCullough AE, Ocal IT, Pockaj BA.

Am J Surg. 2019 Jun;217(6):1025-1029. doi: 10.1016/j.amjsurg.2018.12.069. Epub 2019 Feb 23.

PMID:
30879795
3.

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).

Halfdanarson TR, Foster NR, Kim GP, Meyers JP, Smyrk TC, McCullough AE, Ames MM, Jaffe JP, Alberts SR.

Oncologist. 2019 May;24(5):589-e160. doi: 10.1634/theoncologist.2018-0878. Epub 2019 Jan 24.

4.

Genome wide characterization of enterotoxigenic Escherichia coli serogroup O6 isolates from multiple outbreaks and sporadic infections from 1975-2016.

Pattabiraman V, Katz LS, Chen JC, McCullough AE, Trees E.

PLoS One. 2018 Dec 31;13(12):e0208735. doi: 10.1371/journal.pone.0208735. eCollection 2018.

5.

Proposed Epidemiological Cutoff Values for Ceftriaxone, Cefepime, and Colistin in Salmonella.

Tyson GH, Bodeis-Jones S, Caidi H, Cook K, Dessai U, Haro J, McCullough AE, Meng J, Morales CA, Lawrence JP, Tillman GE, Winslow A, Miller RA.

Foodborne Pathog Dis. 2018 Nov;15(11):701-704. doi: 10.1089/fpd.2018.2490. Epub 2018 Aug 28.

PMID:
30153043
6.

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.

Barrett MT, Lenkiewicz E, Malasi S, Basu A, Yearley JH, Annamalai L, McCullough AE, Kosiorek HE, Narang P, Wilson Sayres MA, Chen M, Anderson KS, Pockaj BA.

Breast Cancer Res. 2018 Jul 11;20(1):71. doi: 10.1186/s13058-018-1004-0.

7.

Gastrointestinal: Cystic endosalpingiosis of the spleen: CT, MR, and US imaging.

Nguyen BD, McCullough AE.

J Gastroenterol Hepatol. 2017 Dec;32(12):1911. doi: 10.1111/jgh.13829. No abstract available.

PMID:
29125210
8.

Discussion of: "The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review".

Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, Anderson KS, McCullough AE, Tolgay Ocal I, Pockaj BA.

Am J Surg. 2017 Dec;214(6):1102-1103. doi: 10.1016/j.amjsurg.2017.09.024. Epub 2017 Sep 30. No abstract available.

PMID:
29037421
9.

The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review.

Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, Anderson KS, McCullough AE, Ocal IT, Pockaj BA.

Am J Surg. 2017 Dec;214(6):1096-1101. doi: 10.1016/j.amjsurg.2017.08.024. Epub 2017 Sep 18.

PMID:
28943062
10.

Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.

Chen M, Andreozzi M, Pockaj B, Barrett MT, Ocal IT, McCullough AE, Linnaus ME, Chang JM, Yearley JH, Annamalai L, Anderson KS.

Mod Pathol. 2017 Nov;30(11):1516-1526. doi: 10.1038/modpathol.2017.86. Epub 2017 Jul 28.

11.

BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management.

Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO.

Radiographics. 2017 Jul-Aug;37(4):1005-1023. doi: 10.1148/rg.2017160144. Epub 2017 May 26. Review.

PMID:
28548905
12.

IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.

Reinholz MM, Chen B, Dueck AC, Tenner K, Ballman K, Riehle D, Jenkins RB, Geiger XJ, McCullough AE, Perez EA.

Clin Cancer Res. 2017 Aug 1;23(15):4203-4211. doi: 10.1158/1078-0432.CCR-15-0574. Epub 2017 May 22.

13.

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.

Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD.

Clin Genitourin Cancer. 2017 Aug;15(4):e727-e734. doi: 10.1016/j.clgc.2016.11.001. Epub 2016 Dec 1. No abstract available.

14.

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.

Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH.

Sci Rep. 2016 Dec 23;6(1):25. doi: 10.1038/s41598-016-0021-4.

15.

Angiosarcoma Causing Cardiac Constriction Late after Radiation Therapy for Breast Carcinoma.

Sharma A, DeValeria PA, Scherber RM, Sugrue G, McCullough AE, Panse PM, Mookadam F.

Tex Heart Inst J. 2016 Feb 1;43(1):81-3. doi: 10.14503/THIJ-14-4549. eCollection 2016 Feb.

16.

Regional recurrence in the era of sentinel lymph node biopsy.

Linnaus ME, Dueck AC, Kosiorek HE, Gray RJ, Wasif N, Northfelt DW, Anderson KS, McCullough AE, Wong WW, Halyard MY, Patel SH, Pockaj BA.

Am J Surg. 2015 Dec;210(6):1155-60; discussion 1160-1. doi: 10.1016/j.amjsurg.2015.09.001. Epub 2015 Sep 28.

PMID:
26601646
17.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.

J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):356.

18.

Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.

Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, McCullough AE, Winham SJ, Vachon CM, Ghosh K, Brandt KR, Farrell AM, Tarabishy Y, Hieken TJ, Haddad TC, Kraft RA, Radisky DC, Degnim AC.

Cancer. 2016 Feb 1;122(3):378-85. doi: 10.1002/cncr.29766. Epub 2015 Oct 29.

19.

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA.

Oncotarget. 2015 Sep 22;6(28):26483-93. doi: 10.18632/oncotarget.4494.

20.

Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.

Chang JM, McCullough AE, Dueck AC, Kosiorek HE, Ocal IT, Lidner TK, Gray RJ, Wasif N, Northfelt DW, Anderson KS, Pockaj BA.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S509-15. doi: 10.1245/s10434-015-4616-y. Epub 2015 May 22.

PMID:
26001860
21.

Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.

Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA.

PLoS One. 2015 Apr 30;10(4):e0127133. doi: 10.1371/journal.pone.0127133. eCollection 2015. No abstract available.

22.

Rates of residual disease with close but negative margins in breast cancer surgery.

Garvey EM, Senior DA, Pockaj BA, Wasif N, Dueck AC, McCullough AE, Ocal IT, Gray RJ.

Breast. 2015 Aug;24(4):413-7. doi: 10.1016/j.breast.2015.03.005. Epub 2015 Apr 4.

23.

Folate receptor-α (FOLR1) expression and function in triple negative tumors.

Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA.

PLoS One. 2015 Mar 27;10(3):e0122209. doi: 10.1371/journal.pone.0122209. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0127133. Aspita, Alvaro Moreno [corrected to Moreno-Aspitia, Alvaro].

24.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM.

J Clin Oncol. 2015 Mar 1;33(7):701-8. doi: 10.1200/JCO.2014.57.6298. Epub 2015 Jan 20.

25.

Sinonasal phosphaturic mesenchymal tumor: Case report and systematic review.

Deep NL, Cain RB, McCullough AE, Hoxworth JM, Lal D.

Allergy Rhinol (Providence). 2014 Jan;5(3):162-7. doi: 10.2500/ar.2014.5.0100.

26.

ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.

Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR.

BMC Cancer. 2014 Oct 7;14:749. doi: 10.1186/1471-2407-14-749.

27.

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA.

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.

28.

Synovial sarcoma presenting as an avascular mass: radiologic-pathologic correlation.

McCullough AE, Schwartz AJ, Taylor VL, Kransdorf MJ.

Skeletal Radiol. 2015 Feb;44(2):279-84. doi: 10.1007/s00256-014-1964-9. Epub 2014 Aug 1.

PMID:
25081635
29.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD.

PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. eCollection 2014 Feb.

30.

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G.

Breast Cancer Res Treat. 2014 Feb;143(3):485-92. doi: 10.1007/s10549-013-2827-0. Epub 2014 Jan 7.

31.

Papillary lesions on core breast biopsy: excisional biopsy for all patients?

McGhan LJ, Pockaj BA, Wasif N, Giurescu ME, McCullough AE, Gray RJ.

Am Surg. 2013 Dec;79(12):1238-42.

PMID:
24351348
32.

Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.

McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, Castle EP, Gray RJ, Wasif N, Goetz MP, Hawse JR, Henry TJ, Barrett MT, Cunliffe HE, Pockaj BA.

Ann Surg Oncol. 2014 Feb;21(2):361-7. doi: 10.1245/s10434-013-3260-7. Epub 2013 Sep 18.

PMID:
24046116
33.

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA.

Clin Cancer Res. 2013 Oct 15;19(20):5798-807. doi: 10.1158/1078-0432.CCR-13-0558. Epub 2013 Aug 21.

34.

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM.

J Clin Oncol. 2013 Jun 10;31(17):2115-22. doi: 10.1200/JCO.2012.42.2642. Epub 2013 May 6.

35.

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA.

Breast Cancer Res Treat. 2013 Apr;138(2):427-35. doi: 10.1007/s10549-013-2469-2. Epub 2013 Mar 12.

36.

Deep clonal profiling of formalin fixed paraffin embedded clinical samples.

Holley T, Lenkiewicz E, Evers L, Tembe W, Ruiz C, Gsponer JR, Rentsch CA, Bubendorf L, Stapleton M, Amorese D, Legendre C, Cunliffe HE, McCullough AE, Pockaj B, Craig D, Carpten J, Von Hoff D, Iacobuzio-Donahue C, Barrett MT.

PLoS One. 2012;7(11):e50586. doi: 10.1371/journal.pone.0050586. Epub 2012 Nov 30.

37.

Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy?

McGhan LJ, Pockaj BA, Wasif N, Giurescu ME, McCullough AE, Gray RJ.

Ann Surg Oncol. 2012 Oct;19(10):3264-9. doi: 10.1245/s10434-012-2575-0. Epub 2012 Aug 10.

PMID:
22878619
38.

Histologic remission of cardiac amyloidosis: a case report.

Nelson MR, Lanza LA, Reeder CB, Scott RL, McCullough AE, Chandrasekaran K, Click RL.

Amyloid. 2012 Jun;19(2):106-9. doi: 10.3109/13506129.2012.660892. Epub 2012 Mar 7.

PMID:
22394355
39.

Granular-cell tumor of the anterior abdominal wall.

McGhan LJ, Wasif N, Young SW, Collins JM, McCullough AE.

Radiol Case Rep. 2015 Dec 7;7(3):716. doi: 10.2484/rcr.v7i3.716. eCollection 2012.

40.

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.

Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B.

J Natl Cancer Inst. 2012 Jan 18;104(2):159-62. doi: 10.1093/jnci/djr490. Epub 2011 Dec 2.

41.

Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique?

Wasif N, McCullough AE, Gray RJ, Pockaj BA.

J Surg Oncol. 2012 May;105(6):586-90. doi: 10.1002/jso.22132. Epub 2011 Nov 7.

PMID:
22065479
42.

The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection?

McGhan LJ, Dueck AC, Gray RJ, Wasif N, McCullough AE, Pockaj BA.

J Surg Oncol. 2012 Sep 1;106(3):254-9. doi: 10.1002/jso.22131. Epub 2011 Oct 27.

PMID:
22034211
43.

Primary ovarian malignant lymphoma presenting as ovarian carcinomatosis: a case report and literature review.

Kapetanakis V, Karlin NJ, McCullough AE, Magtibay PM.

Eur J Gynaecol Oncol. 2010;31(6):701-2. Review.

PMID:
21319522
44.

Progression of pelvic implants to complex atypical endometrial hyperplasia after uterine morcellation.

Kill LM, Kapetanakis V, McCullough AE, Magrina JF.

Obstet Gynecol. 2011 Feb;117(2 Pt 2):447-9. doi: 10.1097/AOG.0b013e3181f2e0c6.

PMID:
21252784
45.

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholz MM.

J Clin Oncol. 2011 Feb 20;29(6):651-9. doi: 10.1200/JCO.2010.30.2125. Epub 2011 Jan 18.

46.

Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.

Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, Fan JB, Lingle WL.

BMC Med Genomics. 2010 Dec 20;3:60. doi: 10.1186/1755-8794-3-60.

47.

Inadequate margins of excision when undergoing mastectomy for breast cancer: which patients are at risk?

Sheikh F, Rebecca A, Pockaj B, Wasif N, McCullough AE, Casey W, Kreymerman P, Gray RJ.

Ann Surg Oncol. 2011 Apr;18(4):952-6. doi: 10.1245/s10434-010-1406-4. Epub 2010 Nov 16.

PMID:
21080087
48.

Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status.

Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, Coppola KE, McLaughlin SA, Palmieri FM, Perez EA.

Oncologist. 2010;15(10):1043-9. doi: 10.1634/theoncologist.2010-0036. Epub 2010 Oct 7.

49.

Triple-negative breast cancers: unique clinical presentations and outcomes.

Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, McCullough AE, Pockaj BA.

Ann Surg Oncol. 2010 Oct;17 Suppl 3:384-90. doi: 10.1245/s10434-010-1260-4. Epub 2010 Sep 19.

PMID:
20853062
50.

The utility of Coccidioides polymerase chain reaction testing in the clinical setting.

Vucicevic D, Blair JE, Binnicker MJ, McCullough AE, Kusne S, Vikram HR, Parish JM, Wengenack NL.

Mycopathologia. 2010 Nov;170(5):345-51. doi: 10.1007/s11046-010-9327-0. Epub 2010 Jun 10.

PMID:
20535639

Supplemental Content

Loading ...
Support Center